Literature DB >> 20231041

Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients.

Greetje Groenendaal1, Cornelis A T van den Berg, Jan G Korporaal, Marielle E P Philippens, Peter R Luijten, Marco van Vulpen, Uulke A van der Heide.   

Abstract

BACKGROUND AND
PURPOSE: A study was performed to investigate if we can quantify if the two imaging modalities diffusion weighted imaging (DWI) and dynamic contrast-enhanced (DCE)-MRI are consistent in what voxels they determine as being suspicious of tumor tissue.
MATERIAL AND METHODS: Twenty-one patients with biopsy proven prostate cancer underwent a DWI and a DCE-MRI scan. These scans were compared using a receiver operating curve (ROC) analysis, where either one of the two imaging modalities was thresholded and taken as a reference. The resulting area under the curve (AUC) reflects the consistency between target delineations based on the two imaging techniques. This analysis was performed for the complete prostate and the peripheral zone (PZ).
RESULTS: Consistency between DWI and DCE-MRI parameter maps varied greatly between patients. Values of the AUC up to 0.90 were found. However, on average AUC values were 0.60. The AUC values were related to the patient's PSA and clinical stage.
CONCLUSIONS: Large variation in consistency between the two imaging modalities was found. This did not depend on the precise thresholds used. For making decisions on dose painting in the prostate, the knowledge about the inconsistency must be taken into account. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20231041     DOI: 10.1016/j.radonc.2010.02.014

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  15 in total

Review 1.  Functional MRI for radiotherapy dose painting.

Authors:  Uulke A van der Heide; Antonetta C Houweling; Greetje Groenendaal; Regina G H Beets-Tan; Philippe Lambin
Journal:  Magn Reson Imaging       Date:  2012-07-06       Impact factor: 2.546

Review 2.  [Diffusion-weighted MRI of the prostate].

Authors:  U G Mueller-Lisse; U L Mueller-Lisse; P Zamecnik; H-P W Schlemmer; M K Scherr
Journal:  Radiologe       Date:  2011-03       Impact factor: 0.635

Review 3.  Biological imaging in clinical oncology: radiation therapy based on functional imaging.

Authors:  Yo-Liang Lai; Chun-Yi Wu; K S Clifford Chao
Journal:  Int J Clin Oncol       Date:  2016-07-06       Impact factor: 3.402

4.  Magnetic resonance imaging for prostate cancer clinical application.

Authors:  Bing Li; Yong Du; Hanfeng Yang; Yayong Huang; Jun Meng; Dongmei Xiao
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

5.  Does 11C-choline PET-CT contribute to multiparametric MRI for prostate cancer localisation?

Authors:  L Van den Bergh; S Isebaert; M Koole; R Oyen; S Joniau; E Lerut; C M Deroose; F De Keyzer; H Van Poppel; K Haustermans
Journal:  Strahlenther Onkol       Date:  2013-09       Impact factor: 3.621

6.  Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion.

Authors:  Daniel Gorovets; Andreas G Wibmer; Assaf Moore; Stephanie Lobaugh; Zhigang Zhang; Marisa Kollmeier; Sean McBride; Michael J Zelefsky
Journal:  Eur Urol Oncol       Date:  2022-03-17

7.  Dosimetric benefit of DMLC tracking for conventional and sub-volume boosted prostate intensity-modulated arc radiotherapy.

Authors:  Tobias Pommer; Marianne Falk; Per R Poulsen; Paul J Keall; Ricky T O'Brien; Peter Meidahl Petersen; Per Munck af Rosenschöld
Journal:  Phys Med Biol       Date:  2013-03-14       Impact factor: 3.609

Review 8.  [Treatment planning with functional MRI].

Authors:  P Georg; P Andrzejewski; K Pinker; D Georg
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

9.  Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial.

Authors:  Irene M Lips; Uulke A van der Heide; Karin Haustermans; Emile N J T van Lin; Floris Pos; Stefan P G Franken; Alexis N T J Kotte; Carla H van Gils; Marco van Vulpen
Journal:  Trials       Date:  2011-12-05       Impact factor: 2.279

10.  3 Tesla multiparametric MRI for GTV-definition of Dominant Intraprostatic Lesions in patients with Prostate Cancer--an interobserver variability study.

Authors:  Hans Christian Rischke; Ursula Nestle; Tobias Fechter; Christian Doll; Natalja Volegova-Neher; Karl Henne; Jutta Scholber; Stefan Knippen; Simon Kirste; Anca L Grosu; Cordula A Jilg
Journal:  Radiat Oncol       Date:  2013-07-22       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.